Toxic Small RNA

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in Glioblastoma Multiforme Patients

Retrieved on: 
Friday, May 19, 2023

Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is catalytically capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA.

Key Points: 
  • Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is catalytically capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA.
  • (2) Safety can be improved by selectively inducing therapeutic RNA expression only in cells/tissues where the target gene is expressed.
  • Through the advanced development phase, I hope Rznomics can provide more new therapeutic options to patients suffering from intractable diseases.
  • In addition to the HCC & GBM, Rznomics is developing ribozyme-based RNA editing treatments for Alzheimer's disease (RZ-003) and inherited retinal dystrophies, called Retinitis pigmentosa (RZ-004).

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in Glioblastoma Multiforme Patients

Retrieved on: 
Friday, May 19, 2023

Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is catalytically capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA.

Key Points: 
  • Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is catalytically capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA.
  • (2) Safety can be improved by selectively inducing therapeutic RNA expression only in cells/tissues where the target gene is expressed.
  • Through the advanced development phase, I hope Rznomics can provide more new therapeutic options to patients suffering from intractable diseases.
  • In addition to the HCC & GBM, Rznomics is developing ribozyme-based RNA editing treatments for Alzheimer's disease (RZ-003) and inherited retinal dystrophies, called Retinitis pigmentosa (RZ-004).

Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecular Glue Discovery and Rational Design at Targeted Protein Degradation Summit

Retrieved on: 
Wednesday, October 26, 2022

The data include platform achievements for ligase-centric and target-centric discovery of molecular glue compounds with potential to modulate previously intractable disease targets.

Key Points: 
  • The data include platform achievements for ligase-centric and target-centric discovery of molecular glue compounds with potential to modulate previously intractable disease targets.
  • A lack of systematic, scalable discovery and design approaches to molecular glues has, however, limited the field, said Riccardo Sabatini, Ph.D., Chief Data Scientist at Orionis.
  • Today we are presenting new data that demonstrate the ability of Orionis proprietary Allo-GlueTM platform to transform glue discovery into a genome-scale, high throughput and rational discovery paradigm.
  • Our large-scale interrogation of small molecule-triggered protein-protein interactions makes it abundantly clear that molecular glue mechanisms are more common than previously appreciated.

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in liver cancer patients

Retrieved on: 
Tuesday, October 25, 2022

Therefore, U.S. FDA approval allows Rznomics to start an international clinical study in HCC patients treating them with RZ-001 and therapeutic RNA editing.

Key Points: 
  • Therefore, U.S. FDA approval allows Rznomics to start an international clinical study in HCC patients treating them with RZ-001 and therapeutic RNA editing.
  • Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA.
  • Through the advanced development phase, I hope Rznomics can provide more new therapeutic options to patients suffering from intractable diseases.
  • Also under development are ribozyme-based RNA editing treatments for Alzheimer's disease (RZ-003) and inherited retinal dystrophies, called Retinitis pigmentosa (RZ-004).

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in liver cancer patients

Retrieved on: 
Tuesday, October 25, 2022

Therefore, U.S. FDA approval allows Rznomics to start an international clinical study in HCC patients treating them with RZ-001 and therapeutic RNA editing.

Key Points: 
  • Therefore, U.S. FDA approval allows Rznomics to start an international clinical study in HCC patients treating them with RZ-001 and therapeutic RNA editing.
  • Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A single RNA molecule is capable of both suppressing target RNA expression and simultaneously expressing a therapeutic RNA.
  • Through the advanced development phase, I hope Rznomics can provide more new therapeutic options to patients suffering from intractable diseases.
  • Also under development are ribozyme-based RNA editing treatments for Alzheimer's disease (RZ-003) and inherited retinal dystrophies, called Retinitis pigmentosa (RZ-004).